Zobrazeno 1 - 10
of 17
pro vyhledávání: '"F Artime Rodríguez"'
Autor:
A Dordà Benito, X Larrea Urtaran, E Nogué Pujadas, À Castelló Nòria, M Vila Currius, F Artime Rodríguez-Hermida, C Subirana Batlle, L Viñas Sagué, R Sacrest Guell
Publikováno v:
Section 5: Patient safety and quality assurance.
Autor:
F Artime Rodríguez-Hermida, M Perpinyà Gombau, C Díez Vallejo, M Olmo Martínez, MD Malla Canet, A Dordà Benito, E Nogué Pujadas, À Castellò Nòria, R Sacrest Güell
Publikováno v:
Late breaking abstracts.
Autor:
C Díez Vallejo, F Artime Rodríguez-Hermida, M Perpinyà Gombau, M Olmo Martínez, M Coma Punset, E Nogué Pujadas, A Dordà Benito, À Castellò Nòria, R Sacrest Güell
Publikováno v:
Late breaking abstracts.
Autor:
F Artime Rodríguez-Hermida, A Dordà Benito, M Coma Punset, M Perpinyà Gombau, M Olmo Martínez, MD Malla Canet, L Mallart Romero, R Sacrest Güell
Publikováno v:
Section 4: Clinical pharmacy services.
5PSQ-071 Efficacy and safety evaluation of trifluridine/tiparacil for metastatic colon cancer (mcrc)
Autor:
C Collado García, S Cano Domínguez, S Guijarro Herrera, F Artime Rodríguez-Hermida, A Jiménez Morales, R García Fumero, L Gutiérrez Zúñiga, CM Valencia Soto
Publikováno v:
Eur J Hosp Pharm
Background Trifluridine/tiparacile is the second oral treatment approved for patients with mCRC who have received fluoropyrimidine, oxaliplin- and irinotecan-based chemotherapy, an anti-VEGF biologic therapy and, if RAS wild-type, an anti-EGFR. Purpo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8dc038c5eb5e45c3212b0f47f8338750
https://europepmc.org/articles/PMC7535737/
https://europepmc.org/articles/PMC7535737/
Autor:
J Cabeza Barrera, E Espínola García, MA García Lirola, P Nieto Gómez, F Artime Rodríguez-Hermida, S Guijarro Herrera, CM Valencia Soto, Rocío López-Sepúlveda
Publikováno v:
Eur J Hosp Pharm
BACKGROUND: Atrial fibrillation (AF) is a common clinical problem, particularly in the elderly. Dabigatran is indicated for the prevention of stroke and systemic embolism, and the reduction of vascular mortality for patients with non-valvular atrial
Autor:
C Iniesta Navalón, C Caballero Requejo, M Onteniente Candela, A López Gómez, A Ramírez Andreo, M Gil Candel, F Artime Rodríguez-Hermida, A Trujillano Ruiz
Publikováno v:
European Journal of Hospital Pharmacy. 23:A207.2-A207
Background Sirolimus is an immunosuppressant used with an off-label indication for angiofibromas in tuberous sclerosis. Purpose To evaluate the effectiveness of topical sirolimus 0.4% ointment for the treatment of angiofibromas in tuberous sclerosis.
Autor:
C Sanchez Alvarez, M Onteniente Candela, M Gil Candel, A Trujillano Ruiz, F Artime Rodríguez-Hermida, C Iniesta Navalón, C Caballero Requejo, N Manresa Ramon
Publikováno v:
European Journal of Hospital Pharmacy. 23:A79.2-A80
Background Artificial nutrition is an essential component in the management of critically ill patients. These patients are at risk of developing malnutrition, which occurs in up to 40% of patients and is associated with increased mortality and morbid
Autor:
Rocío López-Sepúlveda, M Rodríguez Goicoechea, ME Espínola García, S Anaya Ordóñez, F Artime Rodríguez, M Carrasco Gomariz, Martín Sances, J Cabeza Barrera, MA García Lirola
Publikováno v:
European Journal of Hospital Pharmacy. 23:A4.2-A4
Background In some regions, the pharmaceutical services at nursing homes are held by pharmacists from hospitals in the public network. Purpose To determine the impact of medicines reconciliation on the prevalence of potentially inappropriate medicine
Autor:
F Artime Rodríguez-Hermida, A Trujillano Ruiz, C Caballero Requejo, M García Coronel, C García-Molina Sáez, JJ Franco Miguel, M Onteniente Candela, M Gil Candel
Publikováno v:
European Journal of Hospital Pharmacy. 23:A145.2-A146
Background The primary goal of hepatitis C virus (HCV) therapy is to cure the infection. A sustained virological response (SVR) is defined as undetectable HCV RNA 12 weeks (SVR12) after treatment completion. Purpose To assess the effectiveness of new